Login Register Cart 0
Current Drug Targets

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Translate in Chinese
Review Article

Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets

Author(s): Chynna-Loren Sheremeta, Sai Yarlagadda, Mark L. Smythe and Peter G. Noakes*

Volume 25, Issue 13, 2024

Published on: 22 August, 2024

Page: [885 - 908] Pages: 24

DOI: 10.2174/0113894501323980240815113851

open_access

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

The global burden of neurological disorders is evident, yet there remains limited efficacious therapeutics for their treatment. There is a growing recognition of the role of inflammation in diseases of the central nervous system (CNS); among the numerous inflammatory mediators involved, prostaglandins play a crucial role. Prostaglandins are small lipid mediators derived from arachidonic acid via multi-enzymatic pathways. The actions of prostaglandins are varied, with each prostaglandin having a specific role in maintaining homeostasis. In the CNS, prostaglandins can have neuroprotective or neurotoxic properties depending on their specific G-protein receptor. These G-protein receptors have varying subfamilies, tissue distribution, and signal transduction cascades. Further studies into the impact of prostaglandins in CNS-based diseases may contribute to the clarification of their actions, hopefully leading to the development of efficacious therapeutic strategies. This review focuses on the roles played by prostaglandins in neural degeneration, with a focus on Alzheimer’s Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis in both preclinical and clinical settings. We further discuss current prostaglandin-related agonists and antagonists concerning suggestions for their use as future therapeutics.

Keywords: Arachidonic acid, neuroinflammation, neurodegeneration, microglia, prostaglandins, NSAIDs, central nervous system disorders.

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103(2): 147-66.
[http://dx.doi.org/10.1016/j.pharmthera.2004.06.003] [PMID: 15369681]
[2]
Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol 2011; 31(5): 986-1000.
[http://dx.doi.org/10.1161/ATVBAHA.110.207449] [PMID: 21508345]
[3]
Peebles RS Jr. Prostaglandins in asthma and allergic diseases. Pharmacol Ther 2019; 193: 1-19.
[http://dx.doi.org/10.1016/j.pharmthera.2018.08.001] [PMID: 30081047]
[4]
Rittchen S, Heinemann A. Therapeutic potential of hematopoietic prostaglandin D(2) synthase in allergic inflammation. Cells 2019; 8(6): 619.
[http://dx.doi.org/10.3390/cells8060619] [PMID: 31226822]
[5]
Kursun O, Karatas H, Bariskaner H, Ozturk S. Arachidonic acid metabolites in neurologic disorders. CNS Neurol Disord Drug Targets 2022; 21(2): 150-9.
[http://dx.doi.org/10.2174/1871527320666210512013648] [PMID: 33982658]
[6]
de Oliveira ACP, Candelario-Jalil E, Bhatia HS, Lieb K, Hüll M, Fiebich BL. Regulation of prostaglandin E 2 synthase expression in activated primary rat microglia: Evidence for uncoupled regulation of mPGES-1 and COX-2. Glia 2008; 56(8): 844-55.
[http://dx.doi.org/10.1002/glia.20658] [PMID: 18383341]
[7]
Milatovic D, Montine TJ, Aschner M. Prostanoid signaling: Dual role for prostaglandin E2 in neurotoxicity. Neurotoxicology 2011; 32(3): 312-9.
[http://dx.doi.org/10.1016/j.neuro.2011.02.004] [PMID: 21376752]
[8]
Brenneis C, Coste O, Altenrath K, et al. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem 2011; 286(3): 2331-42.
[http://dx.doi.org/10.1074/jbc.M110.157362] [PMID: 21075851]
[9]
Bonfill-Teixidor E, Otxoa-de-Amezaga A, Font-Nieves M, Sans-Fons MG, Planas AM. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide. J Neuroinflammation 2017; 14(1): 3.
[http://dx.doi.org/10.1186/s12974-016-0780-7] [PMID: 28086956]
[10]
Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem 2014; 57(11): 4454-65.
[http://dx.doi.org/10.1021/jm401431x] [PMID: 24279689]
[11]
Xu J, Xu Z, Yan A. Prostaglandin E2 EP4 receptor activation attenuates neuroinflammation and early brain injury induced by subarachnoid hemorrhage in rats. Neurochem Res 2017; 42(4): 1267-78.
[http://dx.doi.org/10.1007/s11064-016-2168-6] [PMID: 28239768]
[12]
Shi J, Johansson J, Woodling NS, Wang Q, Montine TJ, Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010; 184(12): 7207-18.
[http://dx.doi.org/10.4049/jimmunol.0903487] [PMID: 20483760]
[13]
Konya V, Marsche G, Schuligoi R, Heinemann A. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 2013; 138(3): 485-502.
[http://dx.doi.org/10.1016/j.pharmthera.2013.03.006] [PMID: 23523686]
[14]
Tang EHC, Libby P, Vanhoutte PM, Xu A. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol 2012; 59(2): 116-23.
[http://dx.doi.org/10.1097/FJC.0b013e3182244a12] [PMID: 21697732]
[15]
Morimoto K, Shirata N, Taketomi Y, et al. Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation. J Immunol 2014; 192(3): 1130-7.
[http://dx.doi.org/10.4049/jimmunol.1300290] [PMID: 24342806]
[16]
Wang XS, Lau HYA. Prostaglandin E 2 potentiates the immunologically stimulated histamine release from human peripheral blood-derived mast cells through EP1/EP3 receptors. Allergy 2006; 61(4): 503-6.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01043.x] [PMID: 16512814]
[17]
Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010; 91(3-4): 104-12.
[http://dx.doi.org/10.1016/j.prostaglandins.2009.04.003] [PMID: 19808012]
[18]
Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta Mol Cell Biol Lipids 2015; 1851(4): 414-21.
[http://dx.doi.org/10.1016/j.bbalip.2014.07.008] [PMID: 25038274]
[19]
Mizuno R, Kawada K, Sakai Y. Prostaglandin E2/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci 2019; 20(24): 6254.
[http://dx.doi.org/10.3390/ijms20246254] [PMID: 31835815]
[20]
Joo M, Sadikot RT. PGD synthase and PGD2 in immune resposne. Mediators Inflamm 2012; 2012: 1-6.
[http://dx.doi.org/10.1155/2012/503128] [PMID: 22791937]
[21]
Urade Y, Ujihara M, Horiguchi Y, Ikai K, Hayaishi O. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol 1989; 143(9): 2982-9.
[http://dx.doi.org/10.4049/jimmunol.143.9.2982] [PMID: 2509561]
[22]
Xia J, Abdu S, Maguire TJA, Hopkins C, Till SJ, Woszczek G. Prostaglandin D 2 receptors in human mast cells. Allergy 2020; 75(6): 1477-80.
[http://dx.doi.org/10.1111/all.14161] [PMID: 31876962]
[23]
Tanaka K, Ogawa K, Sugamura K, Nakamura M, Takano S, Nagata K. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol 2000; 164(5): 2277-80.
[http://dx.doi.org/10.4049/jimmunol.164.5.2277] [PMID: 10679060]
[24]
Aritake K, Kado Y, Inoue T, Miyano M, Urade Y. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem 2006; 281(22): 15277-86.
[http://dx.doi.org/10.1074/jbc.M506431200] [PMID: 16547010]
[25]
Minghetti L, Levi G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J Neurochem 1995; 65(6): 2690-8.
[http://dx.doi.org/10.1046/j.1471-4159.1995.65062690.x] [PMID: 7595567]
[26]
Eguchi N, Minami T, Shirafuji N, et al. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 1999; 96(2): 726-30.
[http://dx.doi.org/10.1073/pnas.96.2.726] [PMID: 9892701]
[27]
Iwasa K, Yamamoto S, Yamashina K, et al. A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD2-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus. J Neuroinflammation 2021; 18(1): 304.
[http://dx.doi.org/10.1186/s12974-021-02361-2] [PMID: 34961526]
[28]
Narumiya S, Ogorochi T, Nakao K, Hayaishi O. Prostaglandin D2 in rat brain, spinal cord and pituitary: Basal level and regional distribution. Life Sci 1982; 31(19): 2093-103.
[http://dx.doi.org/10.1016/0024-3205(82)90101-1] [PMID: 6960222]
[29]
Hayaishi O, Matsumura H, Urade Y. Prostaglandin D synthase is the key enzyme in the promotion of physiological sleep. J Lipid Mediat 1993; 6(1-3): 429-31.
[PMID: 8358001]
[30]
Crider JY, Griffin BW, Sharif NA. Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists. Br J Pharmacol 1999; 127(1): 204-10.
[http://dx.doi.org/10.1038/sj.bjp.0702490] [PMID: 10369474]
[31]
Hata AN, Zent R, Breyer MD, Breyer RM. Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther 2003; 306(2): 463-70.
[http://dx.doi.org/10.1124/jpet.103.050955] [PMID: 12721327]
[32]
Satoh T, Moroi R, Aritake K, et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 2006; 177(4): 2621-9.
[http://dx.doi.org/10.4049/jimmunol.177.4.2621] [PMID: 16888024]
[33]
Joo M, Kwon M, Sadikot RT, et al. Induction and function of lipocalin prostaglandin D synthase in host immunity. J Immunol 2007; 179(4): 2565-75.
[http://dx.doi.org/10.4049/jimmunol.179.4.2565] [PMID: 17675519]
[34]
Mohri I, Taniike M, Taniguchi H, et al. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J Neurosci 2006; 26(16): 4383-93.
[http://dx.doi.org/10.1523/JNEUROSCI.4531-05.2006] [PMID: 16624958]
[35]
Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003; 69(2-3): 187-94.
[http://dx.doi.org/10.1016/S0952-3278(03)00080-2] [PMID: 12895602]
[36]
Ma J, Yang Q, Wei Y, et al. Effect of the PGD2-DP signaling pathway on primary cultured rat hippocampal neuron injury caused by aluminum overload. Sci Rep 2016; 6(1): 24646.
[http://dx.doi.org/10.1038/srep24646] [PMID: 27089935]
[37]
Herlong JL, Scott TR. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 2006; 102(2): 121-31.
[http://dx.doi.org/10.1016/j.imlet.2005.10.004] [PMID: 16310861]
[38]
Sawyer N, Cauchon E, Chateauneuf A, et al. Molecular pharmacology of the human prostaglandin D 2 receptor, CRTH2. Br J Pharmacol 2002; 137(8): 1163-72.
[http://dx.doi.org/10.1038/sj.bjp.0704973] [PMID: 12466225]
[39]
Marion-Letellier R, Savoye G, Ghosh S. Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol 2016; 785: 44-9.
[http://dx.doi.org/10.1016/j.ejphar.2015.11.004] [PMID: 26632493]
[40]
Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem 2019; 166: 502-13.
[http://dx.doi.org/10.1016/j.ejmech.2019.01.067] [PMID: 30739829]
[41]
Stitham J, Midgett C, Martin KA, Hwa J. Prostacyclin: an inflammatory paradox. Front Pharmacol 2011; 2: 24.
[http://dx.doi.org/10.3389/fphar.2011.00024] [PMID: 21687516]
[42]
Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol 2013; 111(5): 1A-16A.
[http://dx.doi.org/10.1016/j.amjcard.2012.12.002] [PMID: 23414683]
[43]
Safdar Z. Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respir Med 2011; 105(6): 818-27.
[http://dx.doi.org/10.1016/j.rmed.2010.12.018] [PMID: 21273054]
[44]
Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol 2019; 176(8): 1038-50.
[http://dx.doi.org/10.1111/bph.14167] [PMID: 29468666]
[45]
Satoh T, Ishikawa Y, Kataoka Y, et al. CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur J Neurosci 1999; 11(9): 3115-24.
[http://dx.doi.org/10.1046/j.1460-9568.1999.00791.x] [PMID: 10510175]
[46]
Gryglewski RJ. Prostacyclin as a circulatory hormone. Biochem Pharmacol 1979; 28(21): 3161-6.
[http://dx.doi.org/10.1016/0006-2952(79)90055-8] [PMID: 393267]
[47]
Miller VT, Coull BM, Yatsu FM, Shah AB, Beamer NB. Prostacyclin infusion in acute cerebral infarction. Neurology 1984; 34(11): 1431-5.
[http://dx.doi.org/10.1212/WNL.34.11.1431] [PMID: 6387533]
[48]
Takechi H, Matsumura K, Watanabe Y, et al. A novel subtype of the prostacyclin receptor expressed in the central nervous system. J Biol Chem 1996; 271(10): 5901-6.
[http://dx.doi.org/10.1074/jbc.271.10.5901] [PMID: 8621463]
[49]
Takahashi C, Muramatsu R, Fujimura H, Mochizuki H, Yamashita T. Prostacyclin promotes oligodendrocyte precursor recruitment and remyelination after spinal cord demyelination. Cell Death Dis 2013; 4(9): e795-5.
[http://dx.doi.org/10.1038/cddis.2013.335] [PMID: 24030147]
[50]
Yu L, Yang B, Wang J, et al. Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus. Behav Brain Funct 2014; 10(1): 42.
[http://dx.doi.org/10.1186/1744-9081-10-42] [PMID: 25388440]
[51]
Jungner M, Bentzer P, Grände PO. Prostacyclin reduces elevation of intracranial pressure and plasma volume loss in lipopolysaccharide-induced meningitis in the cat. J Trauma 2009; 67(6): 1345-51.
[http://dx.doi.org/10.1097/TA.0b013e3181a5f211] [PMID: 20009688]
[52]
Womack TR, Vollert CT, Ohia-Nwoko O, et al. Prostacyclin promotes degenerative pathology in a model of Alzheimer’s disease. Front Cell Neurosci 2022; 16: 769347.
[http://dx.doi.org/10.3389/fncel.2022.769347] [PMID: 35197825]
[53]
Lima IVA, Bastos LFS, Limborço-Filho M, Fiebich BL, de Oliveira ACP. Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm 2012; 2012: 1-13.
[http://dx.doi.org/10.1155/2012/946813] [PMID: 22778499]
[54]
Basu S. Bioactive eicosanoids: Role of prostaglandin F(2α) and F₂-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells 2010; 30(5): 383-92.
[http://dx.doi.org/10.1007/s10059-010-0157-1] [PMID: 21113821]
[55]
Sakamoto K, Ezashi T, Miwa K, et al. Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 α receptor. J Biol Chem 1994; 269(5): 3881-6.
[http://dx.doi.org/10.1016/S0021-9258(17)41942-9] [PMID: 7508922]
[56]
Sugimoto Y, Hasumoto K, Namba T, et al. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem 1994; 269(2): 1356-60.
[http://dx.doi.org/10.1016/S0021-9258(17)42265-4] [PMID: 8288601]
[57]
Mukhopadhyay P, Bian L, Yin H, Bhattacherjee P, Paterson C. Localization of EP(1) and FP receptors in human ocular tissues by in situ hybridization. Invest Ophthalmol Vis Sci 2001; 42(2): 424-8.
[PMID: 11157877]
[58]
Adams JW, Migita DS, Yu MK, et al. Prostaglandin F2 α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 1996; 271(2): 1179-86.
[http://dx.doi.org/10.1074/jbc.271.2.1179] [PMID: 8557648]
[59]
İnce H, Aydin ÖF, Alaçam H, Aydin T, Azak E, Özyürek H. Urinary leukotriene E4 and prostaglandin F2a concentrations in children with migraine: A randomized study. Acta Neurol Scand 2014; 130(3): 188-92.
[http://dx.doi.org/10.1111/ane.12263] [PMID: 24828386]
[60]
Glushakov AV, Robbins SW, Bracy CL, Narumiya S, Doré S. Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation 2013; 10(1): 132.
[http://dx.doi.org/10.1186/1742-2094-10-132] [PMID: 24172576]
[61]
Wanderer S, Andereggen L, Mrosek J, et al. Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage? J Neurointerv Surg 2022; 14(4): 408-12.
[http://dx.doi.org/10.1136/neurintsurg-2021-017504] [PMID: 34039684]
[62]
Walker KA, Ficek BN, Westbrook R. Understanding the role of systemic inflammation in Alzheimer’s disease. ACS Chem Neurosci 2019; 10(8): 3340-2.
[http://dx.doi.org/10.1021/acschemneuro.9b00333] [PMID: 31241312]
[63]
Matthews PM. Chronic inflammation in multiple sclerosis — seeing what was always there. Nat Rev Neurol 2019; 15(10): 582-93.
[http://dx.doi.org/10.1038/s41582-019-0240-y] [PMID: 31420598]
[64]
McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med 2011; 11(3): 246-54.
[http://dx.doi.org/10.2174/156652411795243450] [PMID: 21375489]
[65]
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140(6): 918-34.
[http://dx.doi.org/10.1016/j.cell.2010.02.016] [PMID: 20303880]
[66]
Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 2016; 13(4): 3391-6.
[http://dx.doi.org/10.3892/mmr.2016.4948] [PMID: 26935478]
[67]
Yagami T, Koma H, Yamamoto Y. Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol Neurobiol 2016; 53(7): 4754-71.
[http://dx.doi.org/10.1007/s12035-015-9355-3] [PMID: 26328537]
[68]
Famitafreshi H, Karimian M. Prostaglandins as the agents that modulate the course of brain disorders. Degener Neurol Neuromuscul Dis 2020; 10: 1-13.
[http://dx.doi.org/10.2147/DNND.S240800] [PMID: 32021549]
[69]
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002; 297(5580): 353-6.
[http://dx.doi.org/10.1126/science.1072994] [PMID: 12130773]
[70]
Biringer RG. A Review of prostanoid receptors: Expression, characterization, regulation, and mechanism of action. J Cell Commun Signal 2021; 15(2): 155-84.
[http://dx.doi.org/10.1007/s12079-020-00585-0] [PMID: 32970276]
[71]
Ow SY, Dunstan DE. A brief overview of amyloids and Alzheimer’s disease. Protein Sci 2014; 23(10): 1315-31.
[http://dx.doi.org/10.1002/pro.2524] [PMID: 25042050]
[72]
Ittner LM, Götz J. Amyloid-β and tau — A toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 2011; 12(2): 67-72.
[http://dx.doi.org/10.1038/nrn2967] [PMID: 21193853]
[73]
Dong Y, Yu H, Li X, et al. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease. J Neuroinflammation 2022; 19(1): 205.
[http://dx.doi.org/10.1186/s12974-022-02567-y] [PMID: 35971179]
[74]
Kerrigan TL, Randall AD. A new player in the “synaptopathy” of Alzheimer’s disease - arc/arg 3.1. Front Neurol 2013; 4: 9.
[http://dx.doi.org/10.3389/fneur.2013.00009] [PMID: 23407382]
[75]
Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S. Neuronal cell death mechanisms in Alzheimer’s disease: An insight. Front Mol Neurosci 2022; 15: 937133.
[http://dx.doi.org/10.3389/fnmol.2022.937133] [PMID: 36090249]
[76]
Apostolova LG, Green AE, Babakchanian S, et al. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord 2012; 26(1): 17-27.
[http://dx.doi.org/10.1097/WAD.0b013e3182163b62] [PMID: 22343374]
[77]
Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, et al. Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain 2013; 136(12): 3738-52.
[http://dx.doi.org/10.1093/brain/awt273] [PMID: 24136825]
[78]
Han F, Liu C, Huang J, et al. The application of patient-derived induced pluripotent stem cells for modeling and treatment of Alzheimer’s disease. Brain Sci Advan 2019; 5(1): 21-40.
[http://dx.doi.org/10.1177/2096595819896178]
[79]
Parnetti L, Chipi E, Salvadori N, D’Andrea K, Eusebi P. Prevalence and risk of progression of preclinical Alzheimer’s disease stages: A systematic review and meta-analysis. Alzheimers Res Ther 2019; 11(1): 7.
[http://dx.doi.org/10.1186/s13195-018-0459-7] [PMID: 30646955]
[80]
Robinson M, Lee BY, Hane FT. Recent progress in Alzheimer’s disease research, part 2: Genetics and epidemiology. J Alzheimers Dis 2017; 57(2): 317-30.
[http://dx.doi.org/10.3233/JAD-161149] [PMID: 28211812]
[81]
Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10(9): 698-712.
[http://dx.doi.org/10.1038/nrd3505] [PMID: 21852788]
[82]
Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer’s disease: It’s time to change our mind. Curr Neuropharmacol 2017; 15(6): 926-35.
[PMID: 28093977]
[83]
Wang Z, Weaver DF. Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer’s disease. Int Immunopharmacol 2022; 110: 109070.
[http://dx.doi.org/10.1016/j.intimp.2022.109070] [PMID: 35978514]
[84]
Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 2005; 4(3): 335-40.
[http://dx.doi.org/10.2174/1568010054022051] [PMID: 16101543]
[85]
Dhapola R, Hota SS, Sarma P, Bhattacharyya A, Medhi B, Reddy DH. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology 2021; 29(6): 1669-81.
[http://dx.doi.org/10.1007/s10787-021-00889-6] [PMID: 34813026]
[86]
Janssen B, Vugts DJ, Funke U, et al. Imaging of neuroinflammation in Alzheimer’s disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochim Biophys Acta Mol Basis Dis 2016; 1862(3): 425-41.
[http://dx.doi.org/10.1016/j.bbadis.2015.11.011] [PMID: 26643549]
[87]
Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Tracking neuroinflammation in Alzheimer’s disease: The role of positron emission tomography imaging. J Neuroinflammation 2014; 11(1): 120.
[http://dx.doi.org/10.1186/1742-2094-11-120] [PMID: 25005532]
[88]
Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM. Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 2013; 34(4): 1051-9.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.09.012] [PMID: 23062700]
[89]
Gomez-Nicola D, Boche D. Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease. Alzheimers Res Ther 2015; 7(1): 42.
[http://dx.doi.org/10.1186/s13195-015-0126-1] [PMID: 25904988]
[90]
Zotova E, Nicoll JAR, Kalaria R, Holmes C, Boche D. Inflammation in Alzheimer’s disease: Relevance to pathogenesis and therapy. Alzheimers Res Ther 2010; 2(1): 1.
[http://dx.doi.org/10.1186/alzrt24] [PMID: 20122289]
[91]
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 2018; 4(1): 575-90.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]
[92]
Cummings J, Aisen PS, DuBois B, et al. Drug development in Alzheimer’s disease: The path to 2025. Alzheimers Res Ther 2016; 8(1): 39.
[http://dx.doi.org/10.1186/s13195-016-0207-9] [PMID: 27646601]
[93]
Yermakova AV, Rollins J, Callahan LM, Rogers J, OʼBanion MK. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58(11): 1135-46.
[http://dx.doi.org/10.1097/00005072-199911000-00003] [PMID: 10560656]
[94]
Fujimi K, Noda K, Sasaki K, et al. Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer’s disease: The Hisayama Study. Dement Geriatr Cogn Disord 2007; 23(6): 423-31.
[http://dx.doi.org/10.1159/000101957] [PMID: 17457030]
[95]
Kenou BV, Manly LS, Rubovits SB, et al. Cyclooxygenases as potential PET imaging biomarkers to explore neuroinflammation in dementia. J Nucl Med 2022; 63: 53S-9S.
[http://dx.doi.org/10.2967/jnumed.121.263199] [PMID: 35649646]
[96]
Hoozemans J, O’Banion M. The role of COX-1 and COX-2 in Alzheimer’s disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005; 4(3): 307-15.
[http://dx.doi.org/10.2174/1568007054038201] [PMID: 15975032]
[97]
Guan PP, Wang P. Integrated communications between cyclooxygenase-2 and Alzheimer’s disease. FASEB J 2019; 33(1): 13-33.
[http://dx.doi.org/10.1096/fj.201800355RRRR] [PMID: 30020833]
[98]
Liu N, Zhuang Y, Zhou Z, Zhao J, Chen Q, Zheng J. NF-κB dependent up-regulation of TRPC6 by Aβ in BV-2 microglia cells increases COX-2 expression and contributes to hippocampus neuron damage. Neurosci Lett 2017; 651: 1-8.
[http://dx.doi.org/10.1016/j.neulet.2017.04.056] [PMID: 28458019]
[99]
Hoozemans JJM, Rozemuller AJM, Janssen I, De Groot CJA, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer’s disease and control brain. Acta Neuropathol 2001; 101(1): 2-8.
[http://dx.doi.org/10.1007/s004010000251] [PMID: 11194936]
[100]
Montero-Cosme TG, Pascual-Mathey LI, Hernández-Aguilar ME, Herrera-Covarrubias D, Rojas-Durán F, Aranda-Abreu GE. Potential drugs for the treatment of Alzheimer’s disease. Pharmacol Rep 2023; 75(3): 544-59.
[http://dx.doi.org/10.1007/s43440-023-00481-5] [PMID: 37005970]
[101]
El-Malah AA, Gineinah MM, Deb PK, et al. Selective COX-2 inhibitors: Road from success to controversy and the quest for repurposing. Pharmaceuticals (Basel) 2022; 15(7): 827.
[http://dx.doi.org/10.3390/ph15070827] [PMID: 35890126]
[102]
Moussa N, Dayoub N. Exploring the role of COX-2 in Alzheimer’s disease: Potential therapeutic implications of COX-2 inhibitors. Saudi Pharm J 2023; 31(9): 101729.
[http://dx.doi.org/10.1016/j.jsps.2023.101729] [PMID: 37638222]
[103]
Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: Systematic review and meta-analysis of observational studies. BMJ 2003; 327(7407): 128.
[http://dx.doi.org/10.1136/bmj.327.7407.128] [PMID: 12869452]
[104]
Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008; 70(23): 2219-25.
[http://dx.doi.org/10.1212/01.wnl.0000313813.48505.86] [PMID: 18519870]
[105]
Jordan F, Quinn TJ, McGuinness B, et al. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev 2020; 4(4): CD011459.
[PMID: 32352165]
[106]
Jaturapatporn D, Isaac MGEKN, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Libr 2012; (2): CD006378.
[http://dx.doi.org/10.1002/14651858.CD006378.pub2] [PMID: 22336816]
[107]
Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front Aging Neurosci 2010; 2: 19.
[http://dx.doi.org/10.3389/fnagi.2010.00019] [PMID: 20725517]
[108]
McGeer PL, Guo JP, Lee M, Kennedy K, McGeer EG. Alzheimer’s disease can be spared by nonsteroidal anti-inflammatory drugs. J Alzheimers Dis 2018; 62(3): 1219-22.
[http://dx.doi.org/10.3233/JAD-170706] [PMID: 29103042]
[109]
Breitner JCS, Martin BK, Meinert CL. The suspension of treatments in ADAPT: Concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin Trials 2006; 1(8): e41.
[http://dx.doi.org/10.1371/journal.pctr.0010041] [PMID: 17192795]
[110]
Biringer RG. The role of eicosanoids in Alzheimer’s disease. Int J Environ Res Public Health 2019; 16(14): 2560.
[http://dx.doi.org/10.3390/ijerph16142560] [PMID: 31323750]
[111]
Do KV, Hjorth E, Wang Y, et al. Cerebrospinal fluid profile of lipid mediators in Alzheimer’s disease. Cell Mol Neurobiol 2023; 43(2): 797-811.
[http://dx.doi.org/10.1007/s10571-022-01216-5] [PMID: 35362880]
[112]
Zhu M, Wang X, Hjorth E, et al. Pro-resolving lipid mediators improve neuronal survival and increase Aβ42 phagocytosis. Mol Neurobiol 2016; 53(4): 2733-49.
[http://dx.doi.org/10.1007/s12035-015-9544-0] [PMID: 26650044]
[113]
Ebright B, Assante I, Poblete RA, et al. Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer’s dementia. Alzheimers Res Ther 2022; 14(1): 152.
[http://dx.doi.org/10.1186/s13195-022-01084-7] [PMID: 36217192]
[114]
Mohri I, Kadoyama K, Kanekiyo T, et al. Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2007; 66(6): 469-80.
[http://dx.doi.org/10.1097/01.jnen.0000240472.43038.27] [PMID: 17549007]
[115]
Liang X, Wu L, Hand T, Andreasson K. Prostaglandin D 2 mediates neuronal protection via the DP1 receptor. J Neurochem 2005; 92(3): 477-86.
[http://dx.doi.org/10.1111/j.1471-4159.2004.02870.x] [PMID: 15659218]
[116]
Li Y, Kim WM, Kim SH, et al. Prostaglandin D 2 contributes to cisplatin-induced neuropathic pain in rats via DP2 receptor in the spinal cord. Korean J Pain 2021; 34(1): 27-34.
[http://dx.doi.org/10.3344/kjp.2021.34.1.27] [PMID: 33380565]
[117]
Kanekiyo T, Ban T, Aritake K, et al. Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid. Proc Natl Acad Sci USA 2007; 104(15): 6412-7.
[http://dx.doi.org/10.1073/pnas.0701585104] [PMID: 17404210]
[118]
Kannaian B, Sharma B, Phillips M, et al. Abundant neuroprotective chaperone Lipocalin-type prostaglandin D synthase (L-PGDS) disassembles the Amyloid-β fibrils. Sci Rep 2019; 9(1): 12579.
[http://dx.doi.org/10.1038/s41598-019-48819-5] [PMID: 31467325]
[119]
Maesaka JK, Sodam B, Palaia T, et al. Prostaglandin D2 synthase: Apoptotic factor in alzheimer plasma, inducer of reactive oxygen species, inflammatory cytokines and dialysis dementia. J Nephropathol 2013; 2(3): 166-80.
[PMID: 24475446]
[120]
Xu J, Barger SW, Drew PD. The PPAR-gamma agonist 15-deoxy-delta-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer’s disease. PPAR Res 2008; 2008(1): 349185.
[http://dx.doi.org/10.1155/2008/349185] [PMID: 18615183]
[121]
Drew PD, Chavis JA. The cyclopentone prostaglandin 15-deoxy-Δ12,14 prostaglandin J2 represses nitric oxide, TNF-α, and IL-12 production by microglial cells. J Neuroimmunol 2001; 115(1-2): 28-35.
[http://dx.doi.org/10.1016/S0165-5728(01)00267-3] [PMID: 11282151]
[122]
Combrinck M, Williams J, De Berardinis MA, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006; 77(1): 85-8.
[http://dx.doi.org/10.1136/jnnp.2005.063131] [PMID: 15944180]
[123]
Akitake Y, Nakatani Y, Kamei D, et al. Microsomal prostaglandin E synthase-1 is induced in alzheimer’s disease and its deletion mitigates alzheimer’s disease-like pathology in a mouse model. J Neurosci Res 2013; 91(7): 909-19.
[http://dx.doi.org/10.1002/jnr.23217] [PMID: 23553915]
[124]
Chaudhry UA, Zhuang H, Crain BJ, Doré S. Elevated microsomal prostaglandin-E synthase-1 in Alzheimer’s disease. Alzheimers Dement 2008; 4(1): 6-13.
[http://dx.doi.org/10.1016/j.jalz.2007.10.015] [PMID: 18631945]
[125]
Chaudhry U, Zhuang H, Doré S. Microsomal prostaglandin E synthase-2: Cellular distribution and expression in Alzheimer’s disease. Exp Neurol 2010; 223(2): 359-65.
[http://dx.doi.org/10.1016/j.expneurol.2009.07.027] [PMID: 19664621]
[126]
Sluter MN, Li Q, Yasmen N, et al. The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders. Exp Biol Med (Maywood) 2023; 248(9): 811-9.
[http://dx.doi.org/10.1177/15353702231179926] [PMID: 37515545]
[127]
Johansson JU, Woodling NS, Wang Q, et al. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models. J Clin Invest 2015; 125(1): 350-64.
[http://dx.doi.org/10.1172/JCI77487] [PMID: 25485684]
[128]
Liang X, Wang Q, Hand T, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s disease. J Neurosci 2005; 25(44): 10180-7.
[http://dx.doi.org/10.1523/JNEUROSCI.3591-05.2005] [PMID: 16267225]
[129]
Xia Y, Xiao Y, Wang ZH, et al. Bacteroides Fragilis in the gut microbiomes of Alzheimer’s disease activates microglia and triggers pathogenesis in neuronal C/EBPβ transgenic mice. Nat Commun 2023; 14(1): 5471.
[http://dx.doi.org/10.1038/s41467-023-41283-w] [PMID: 37673907]
[130]
Cimino P, Keene C, Breyer R, Montine K, Montine T. Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem 2008; 15(19): 1863-9.
[http://dx.doi.org/10.2174/092986708785132915] [PMID: 18691044]
[131]
Wei LL, Shen YD, Zhang YC, et al. Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer’s disease. Neurosci Bull 2010; 26(1): 77-84.
[http://dx.doi.org/10.1007/s12264-010-0703-z] [PMID: 20101275]
[132]
Woodling NS, Andreasson KI. Untangling the web: Toxic and protective effects of neuroinflammation and PGE2 signaling in Alzheimer’s disease. ACS Chem Neurosci 2016; 7(4): 454-63.
[http://dx.doi.org/10.1021/acschemneuro.6b00016] [PMID: 26979823]
[133]
Zhen G, Kim YT, Li R, et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer’s disease. Neurobiol Aging 2012; 33(9): 2215-9.
[http://dx.doi.org/10.1016/j.neurobiolaging.2011.09.017] [PMID: 22015313]
[134]
Shi J, Wang Q, Johansson JU, et al. Inflammatory prostaglandin E 2 signaling in a mouse model of Alzheimer disease. Ann Neurol 2012; 72(5): 788-98.
[http://dx.doi.org/10.1002/ana.23677] [PMID: 22915243]
[135]
Hoshino T, Namba T, Takehara M, et al. Improvement of cognitive function in Alzheimer’s disease model mice by genetic and pharmacological inhibition of the EP 4 receptor. J Neurochem 2012; 120(5): 795-805.
[http://dx.doi.org/10.1111/j.1471-4159.2011.07567.x] [PMID: 22044482]
[136]
Woodling NS, Wang Q, Priyam PG, et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci 2014; 34(17): 5882-94.
[http://dx.doi.org/10.1523/JNEUROSCI.0410-14.2014] [PMID: 24760848]
[137]
Fattahi MJ, Mirshafiey A. Positive and negative effects of prostaglandins in Alzheimer’s disease. Psychiatry Clin Neurosci 2014; 68(1): 50-60.
[http://dx.doi.org/10.1111/pcn.12092] [PMID: 23992456]
[138]
Zhuang J, Zhang H, Zhou R, Chen L, Chen J, Shen X. Regulation of prostaglandin F2α against β amyloid clearance and its inflammation induction through LXR/RXR heterodimer antagonism in microglia. Prostaglandins Other Lipid Mediat 2013; 106: 45-52.
[http://dx.doi.org/10.1016/j.prostaglandins.2013.09.002] [PMID: 24076168]
[139]
Kim KM, Jung BH, Paeng KJ, Kim I, Chung BC. Increased urinary F2-isoprostanes levels in the patients with Alzheimer’s disease. Brain Res Bull 2004; 64(1): 47-51.
[http://dx.doi.org/10.1016/j.brainresbull.2004.04.016] [PMID: 15275956]
[140]
Trares K, Gào X, Perna L, et al. Associations of urinary 8-iso-prostaglandin F 2α levels with all-cause dementia, Alzheimer’s disease, and vascular dementia incidence: results from a prospective cohort study. Alzheimers Dement 2020; 16(5): 804-13.
[http://dx.doi.org/10.1002/alz.12081] [PMID: 32281305]
[141]
Trares K, Chen LJ, Schöttker B. Association of F2-isoprostane levels with Alzheimer’s disease in observational studies: A systematic review and meta-analysis. Ageing Res Rev 2022; 74: 101552.
[http://dx.doi.org/10.1016/j.arr.2021.101552] [PMID: 34954419]
[142]
Womack T, Eriksen JL. Effects of prostacyclin signaling on Alzheimer’s disease associated pathologies. FASEB J 2020; 34(S1): 1-1.
[http://dx.doi.org/10.1096/fasebj.2020.34.s1.05459]
[143]
Wei G, Kibler KK, Koehler RC, Maruyama T, Narumiya S, Doré S. Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse. Neuroscience 2008; 156(4): 1111-7.
[http://dx.doi.org/10.1016/j.neuroscience.2008.07.073] [PMID: 18790018]
[144]
Ling QL, Akasaka H, Chen C, Haile CN, Winoske K, Ruan KH. The protective effects of up-regulating prostacyclin biosynthesis on neuron survival in hippocampus. J Neuroimmune Pharmacol 2020; 15(2): 292-308.
[http://dx.doi.org/10.1007/s11481-019-09896-5] [PMID: 31897976]
[145]
Vaz M, Silvestre S. Alzheimer’s disease: Recent treatment strategies. Eur J Pharmacol 2020; 887: 173554.
[http://dx.doi.org/10.1016/j.ejphar.2020.173554] [PMID: 32941929]
[146]
Banik A, Amaradhi R, Lee D, et al. Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease. J Neuroinflammation 2021; 18(1): 273.
[http://dx.doi.org/10.1186/s12974-021-02297-7] [PMID: 34801055]
[147]
Liu Q, Liang X, Wang Q, et al. PGE 2 signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia. Proc Natl Acad Sci USA 2019; 116(20): 10019-24.
[http://dx.doi.org/10.1073/pnas.1818544116] [PMID: 31036664]
[148]
Amaradhi R, Banik A, Mohammed S, et al. Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models. J Med Chem 2020; 63(3): 1032-50.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01218] [PMID: 31904232]
[149]
Sluter MN, Hou R, Li L, et al. EP2 Antagonists (2011-2021): A decade’s journey from discovery to therapeutics. J Med Chem 2021; 64(16): 11816-36.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00816] [PMID: 34352171]
[150]
Schlicher L, Green LG, Romagnani A, Renner F. Small molecule inhibitors for cancer immunotherapy and associated biomarkers – The current status. Front Immunol 2023; 14: 1297175.
[http://dx.doi.org/10.3389/fimmu.2023.1297175] [PMID: 38022587]
[151]
Morofuji Y, Nakagawa S. Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning. Curr Pharm Des 2020; 26(13): 1466-85.
[http://dx.doi.org/10.2174/1381612826666200224112534] [PMID: 32091330]
[152]
Wallace CH, Oliveros G, Serrano PA, Rockwell P, Xie L, Figueiredo-Pereira M. Timapiprant, a prostaglandin D2 receptor antagonist, ameliorates pathology in a rat Alzheimer’s model. Life Sci Alliance 2022; 5(12): e202201555.
[http://dx.doi.org/10.26508/lsa.202201555] [PMID: 36167438]
[153]
Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain 2005; 128(6): 1442-53.
[http://dx.doi.org/10.1093/brain/awh452] [PMID: 15817521]
[154]
Chamberlain S, Gabriel H, Strittmatter W, Didsbury J. An exploratory phase IIa study of the PPAR delta/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer’s disease. J Alzheimers Dis 2020; 73(3): 1085-103.
[http://dx.doi.org/10.3233/JAD-190864] [PMID: 31884472]
[155]
Alhowail A, Alsikhan R, Alsaud M, Aldubayan M, Rabbani SI. Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: A review of literature. Drug Des Devel Ther 2022; 16: 2919-31.
[http://dx.doi.org/10.2147/DDDT.S367229] [PMID: 36068789]
[156]
Chen YC, Wu JS, Tsai HD, et al. Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol 2012; 46(1): 114-24.
[http://dx.doi.org/10.1007/s12035-012-8259-8] [PMID: 22434581]
[157]
Steinke I, Govindarajulu M, Pinky PD, et al. Selective PPAR-delta/PPAR-gamma activation improves cognition in a model of Alzheimer’s disease. Cells 2023; 12(8): 1116.
[http://dx.doi.org/10.3390/cells12081116] [PMID: 37190025]
[158]
Saunders AM, Burns DK, Gottschalk WK. Reassessment of Pioglitazone for Alzheimer’s Disease. Front Neurosci 2021; 15: 666958.
[http://dx.doi.org/10.3389/fnins.2021.666958] [PMID: 34220427]
[159]
Dobson R, Giovannoni G. Multiple sclerosis – A review. Eur J Neurol 2019; 26(1): 27-40.
[http://dx.doi.org/10.1111/ene.13819] [PMID: 30300457]
[160]
Henderson APD, Barnett MH, Parratt JDE, Prineas JW. Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66(6): 739-53.
[http://dx.doi.org/10.1002/ana.21800] [PMID: 20035511]
[161]
Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol 2015; 14(4): 406-19.
[http://dx.doi.org/10.1016/S1474-4422(14)70305-9] [PMID: 25792099]
[162]
Ruiz F, Vigne S, Pot C. Resolution of inflammation during multiple sclerosis. Semin Immunopathol 2019; 41(6): 711-26.
[http://dx.doi.org/10.1007/s00281-019-00765-0] [PMID: 31732775]
[163]
Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001; 33(4): 289-94.
[http://dx.doi.org/10.1097/00004836-200110000-00006] [PMID: 11588541]
[164]
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol 2017; 74(8): 961-9.
[http://dx.doi.org/10.1001/jamaneurol.2017.0676] [PMID: 28604916]
[165]
Comi G. Disease-modifying treatments for progressive multiple sclerosis. Mult Scler 2013; 19(11): 1428-36.
[http://dx.doi.org/10.1177/1352458513502572] [PMID: 24062415]
[166]
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain 2017; 140(3): 527-46.
[PMID: 27794524]
[167]
Wingerchuk DM, Carter JL. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014; 89(2): 225-40.
[http://dx.doi.org/10.1016/j.mayocp.2013.11.002] [PMID: 24485135]
[168]
Weiner HL. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65(3): 239-48.
[http://dx.doi.org/10.1002/ana.21640] [PMID: 19334069]
[169]
Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases 2015; 3(7): 545-55.
[http://dx.doi.org/10.12998/wjcc.v3.i7.545] [PMID: 26244148]
[170]
Hauser SL, Cree BAC. Treatment of multiple sclerosis: A review. Am J Med 2020; 133(12): 1380-1390.e2.
[http://dx.doi.org/10.1016/j.amjmed.2020.05.049] [PMID: 32682869]
[171]
Hoxha M, Spahiu E, Prendi E, Zappacosta B. A systematic review on the role of arachidonic acid pathway in multiple sclerosis. CNS Neurol Disord Drug Targets 2022; 21(2): 160-87.
[http://dx.doi.org/10.2174/1871527319666200825164123] [PMID: 32842948]
[172]
Mirshafiey A, Jadidi-Niaragh F. Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol 2010; 32(4): 543-54.
[http://dx.doi.org/10.3109/08923971003667627] [PMID: 20233088]
[173]
Palumbo S. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Codon Publications 2017.
[http://dx.doi.org/10.15586/codon.multiplesclerosis.2017.]
[174]
Palumbo S, Bosetti F. Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids 2013; 89(5): 273-8.
[http://dx.doi.org/10.1016/j.plefa.2013.08.008] [PMID: 24095587]
[175]
Broos JY, van der Burgt RTM, Konings J, et al. Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: Fueling or dampening disease progression? J Neuroinflammation 2024; 21(1): 21.
[http://dx.doi.org/10.1186/s12974-023-02981-w] [PMID: 38233951]
[176]
Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS. Handb Clin Neurol 2014; 122: 173-89.
[http://dx.doi.org/10.1016/B978-0-444-52001-2.00008-X] [PMID: 24507518]
[177]
Vantaggiato L, Shaba E, Carleo A, et al. Neurodegenerative disorder risk in Krabbe disease carriers. Int J Mol Sci 2022; 23(21): 13537.
[http://dx.doi.org/10.3390/ijms232113537] [PMID: 36362324]
[178]
Coda AR, Anzilotti S, Boscia F, et al. in vivo imaging of CNS microglial activation/macrophage infiltration with combined [18F]DPA-714-PET and SPIO-MRI in a mouse model of relapsing remitting experimental autoimmune encephalomyelitis. Eur J Nucl Med Mol Imaging 2021; 48(1): 40-52.
[http://dx.doi.org/10.1007/s00259-020-04842-7] [PMID: 32378022]
[179]
Wu YP, McMahon EJ, Matsuda J, Suzuki K, Matsushima GK, Suzuki K. Expression of immune-related molecules is downregulated in twitcher mice following bone marrow transplantation. J Neuropathol Exp Neurol 2001; 60(11): 1062-74.
[http://dx.doi.org/10.1093/jnen/60.11.1062] [PMID: 11706936]
[180]
Kagitani-Shimono K, Mohri I, Fujitani Y, et al. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation 2005; 2(1): 10.
[http://dx.doi.org/10.1186/1742-2094-2-10] [PMID: 15813970]
[181]
Zheng J, Sariol A, Meyerholz D, et al. Prostaglandin D2 signaling in dendritic cells is critical for the development of EAE. J Autoimmun 2020; 114: 102508.
[http://dx.doi.org/10.1016/j.jaut.2020.102508] [PMID: 32624353]
[182]
Taniike M, Mohri I, Eguchi N, Beuckmann CT, Suzuki K, Urade Y. Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model. J Neurosci 2002; 22(12): 4885-96.
[http://dx.doi.org/10.1523/JNEUROSCI.22-12-04885.2002] [PMID: 12077186]
[183]
Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011; 164(4): 1079-106.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01302.x] [PMID: 21371012]
[184]
Takeuchi C, Matsumoto Y, Kohyama K, et al. Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis. Neurochem Int 2013; 62(3): 271-80.
[http://dx.doi.org/10.1016/j.neuint.2012.12.007] [PMID: 23266396]
[185]
Kihara Y, Matsushita T, Kita Y, et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 2009; 106(51): 21807-12.
[http://dx.doi.org/10.1073/pnas.0906891106] [PMID: 19995978]
[186]
Esaki Y, Li Y, Sakata D, et al. Dual roles of PGE 2 -EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107(27): 12233-8.
[http://dx.doi.org/10.1073/pnas.0915112107] [PMID: 20566843]
[187]
Singh Bahia M, Kumar Katare Y, Silakari O, Vyas B, Silakari P. Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates. Med Res Rev 2014; 34(4): 825-55.
[http://dx.doi.org/10.1002/med.21306] [PMID: 25019142]
[188]
Bergqvist F, Morgenstern R, Jakobsson PJ. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. Prostaglandins Other Lipid Mediat 2020; 147: 106383.
[http://dx.doi.org/10.1016/j.prostaglandins.2019.106383] [PMID: 31698145]
[189]
LaBorde K, Lu R, Ruan KH. Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1. Future Med Chem 2022; 14(6): 385-8.
[http://dx.doi.org/10.4155/fmc-2021-0317] [PMID: 34985304]
[190]
Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002; 3(2): 59-70.
[http://dx.doi.org/10.1038/sj.gene.6363832] [PMID: 11960303]
[191]
Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis. J Neuroimmunol 2005; 161(1-2): 113-22.
[http://dx.doi.org/10.1016/j.jneuroim.2004.12.015] [PMID: 15748950]
[192]
Raine CS. Multiple sclerosis: The resolving lesion revealed. J Neuroimmunol 2017; 304: 2-6.
[http://dx.doi.org/10.1016/j.jneuroim.2016.05.021] [PMID: 27265754]
[193]
Morel A, Miller E, Bijak M, Saluk J. The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. Mol Cell Biochem 2016; 420(1-2): 85-94.
[http://dx.doi.org/10.1007/s11010-016-2770-6] [PMID: 27507559]
[194]
Bolton C, Turner AM, Turk JL. Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse. J Neuroimmunol 1984; 6(3): 151-9.
[http://dx.doi.org/10.1016/0165-5728(84)90002-X] [PMID: 6586729]
[195]
Dore-Duffy P, Ho SY, Donovan C. Cerebrospinal fluid eicosanoid levels. Neurology 1991; 41(2_part_1): 322-4.
[http://dx.doi.org/10.1212/WNL.41.2_Part_1.322] [PMID: 1992386]
[196]
Egg D, Herold M, Rumpl E, Günther R. Prostaglandin F2 α levels in human cerebrospinal fluid in normal and pathological conditions. J Neurol 1980; 222(4): 239-48.
[http://dx.doi.org/10.1007/BF00313153] [PMID: 6154783]
[197]
Dore-Duffy P, Donaldson JO, Koff T, Longo M, Perry W. Prostaglandin release in multiple sclerosis. Neurology 1986; 36(12): 1587-90.
[http://dx.doi.org/10.1212/WNL.36.12.1587] [PMID: 3785673]
[198]
Kooij G, Troletti CD, Leuti A, et al. Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica 2020; 105(8): 2056-70.
[http://dx.doi.org/10.3324/haematol.2019.219519] [PMID: 31780628]
[199]
Mattsson N, Yaong M, Rosengren L, et al. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15 -(S)- hydroxyeicosatetraenoic acid in multiple sclerosis. J Intern Med 2009; 265(4): 459-64.
[http://dx.doi.org/10.1111/j.1365-2796.2008.02035.x] [PMID: 19019188]
[200]
Paz Soldan M, Schmidt L, Wood B, Rose J, Carlson N. Prostaglandin F2α receptor mediates oligodendrocyte precursor injury/death: Potential role in multiple sclerosis. Neurology 2015; 84: P5.210.
[http://dx.doi.org/10.1212/WNL.84.14_supplement.P5.210.]
[201]
Lam MA, Maghzal GJ, Khademi M, et al. Absence of systemic oxidative stress and increased CSF prostaglandin F 2α in progressive MS. Neurol Neuroimmunol Neuroinflamm 2016; 3(4): e256.
[http://dx.doi.org/10.1212/NXI.0000000000000256] [PMID: 27386506]
[202]
Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310(2): 173-86.
[http://dx.doi.org/10.1016/S0009-8981(01)00573-3] [PMID: 11498083]
[203]
Kagitani-Shimono K, Mohri I, Oda H, et al. Lipocalin-type prostaglandin D synthase (β-trace) is upregulated in the αB-crystallin- positive oligodendrocytes and astrocytes in the chronic multiple sclerosis. Neuropathol Appl Neurobiol 2006; 32(1): 64-73.
[http://dx.doi.org/10.1111/j.1365-2990.2005.00690.x] [PMID: 16409554]
[204]
Comabella M, Pradillo JM, Fernández M, et al. Plasma levels of 15d-PGJ 2 are not altered in multiple sclerosis. Eur J Neurol 2009; 16(11): 1197-201.
[http://dx.doi.org/10.1111/j.1468-1331.2009.02696.x] [PMID: 19538219]
[205]
Bergman J, Svenningsson A, Liv P, Bergenheim T, Burman J. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS. Fluids Barriers CNS 2020; 17(1): 49.
[http://dx.doi.org/10.1186/s12987-020-00205-4] [PMID: 32727487]
[206]
Talanki Manjunatha R, Habib S, Sangaraju SL, Yepez D, Grandes XA. Multiple sclerosis: Therapeutic strategies on the horizon. Cureus 2022; 14(5): e24895.
[http://dx.doi.org/10.7759/cureus.24895] [PMID: 35706718]
[207]
Pershadsingh HA, Heneka MT, Saini R, Amin NM, Broeske DJ, Feinstein DL. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 2004; 1(1): 3.
[http://dx.doi.org/10.1186/1742-2094-1-3] [PMID: 15285799]
[208]
Iwasa K, Yamamoto S, Takahashi M, et al. Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model. Prostaglandins Leukot Essent Fatty Acids 2014; 91(5): 175-82.
[http://dx.doi.org/10.1016/j.plefa.2014.08.004] [PMID: 25224839]
[209]
Daviaud N, Chen E, Edwards T, Sadiq SA. Cerebral organoids in primary progressive multiple sclerosis reveal stem cell and oligodendrocyte differentiation defect. Biol Open 2023; 12(3): bio059845.
[http://dx.doi.org/10.1242/bio.059845] [PMID: 36744877]
[210]
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol 2020; 27(10): 1918-29.
[http://dx.doi.org/10.1111/ene.14393] [PMID: 32526057]
[211]
McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010; 7(6): 557-70.
[http://dx.doi.org/10.1016/j.genm.2010.11.010] [PMID: 21195356]
[212]
Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65(S1): S3-9.
[http://dx.doi.org/10.1002/ana.21543] [PMID: 19191304]
[213]
Liang X, Wang Q, Shi J, et al. The prostaglandin E 2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008; 64(3): 304-14.
[http://dx.doi.org/10.1002/ana.21437] [PMID: 18825663]
[214]
Lee JD, Levin SC, Willis EF, Li R, Woodruff TM, Noakes PG. Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2018; 15(1): 171.
[http://dx.doi.org/10.1186/s12974-018-1217-2] [PMID: 29859100]
[215]
Lee JD, Kumar V, Fung JNT, Ruitenberg MJ, Noakes PG, Woodruff TM. Pharmacological inhibition of complement C5a-C5a 1 receptor signalling ameliorates disease pathology in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. Br J Pharmacol 2017; 174(8): 689-99.
[http://dx.doi.org/10.1111/bph.13730] [PMID: 28128456]
[216]
Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin 2015; 33(4): 877-88.
[http://dx.doi.org/10.1016/j.ncl.2015.07.009] [PMID: 26515627]
[217]
Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362(6415): 59-62.
[http://dx.doi.org/10.1038/362059a0] [PMID: 8446170]
[218]
Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 2008; 4(9): e1000193.
[http://dx.doi.org/10.1371/journal.pgen.1000193] [PMID: 18802454]
[219]
Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264(5166): 1772-5.
[http://dx.doi.org/10.1126/science.8209258] [PMID: 8209258]
[220]
Van Den Bosch L. Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol 2011; 2011: 348765.
[PMID: 21274268]
[221]
Joyce PI, Fratta P, Fisher EMC, Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: Recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 2011; 22(7-8): 420-48.
[http://dx.doi.org/10.1007/s00335-011-9339-1] [PMID: 21706386]
[222]
Bellingham MC. Pre- and postsynaptic mechanisms underlying inhibition of hypoglossal motor neuron excitability by riluzole. J Neurophysiol 2013; 110(5): 1047-61.
[http://dx.doi.org/10.1152/jn.00587.2012] [PMID: 23741042]
[223]
Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Libr 2012; 2012(3): CD001447.
[http://dx.doi.org/10.1002/14651858.CD001447.pub3] [PMID: 22419278]
[224]
Lee H, Lee JJ, Park NY, et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat Neurosci 2021; 24(12): 1673-85.
[http://dx.doi.org/10.1038/s41593-021-00944-z] [PMID: 34782793]
[225]
Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS—a dual role? Exp Neurol 2004; 187(1): 1-10.
[http://dx.doi.org/10.1016/j.expneurol.2003.12.009] [PMID: 15081582]
[226]
Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63(9): 901-10.
[http://dx.doi.org/10.1093/jnen/63.9.901] [PMID: 15453089]
[227]
Hanna L, Poluyi E, Ikwuegbuenyi C, Morgan E, Imaguezegie G. Peripheral inflammation and neurodegeneration; A potential for therapeutic intervention in Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Egypt j neurosurg 2022; 37(1): 15.
[http://dx.doi.org/10.1186/s41984-022-00150-4]
[228]
Kukharsky MS, Skvortsova VI, Bachurin SO, Buchman VL. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Med Res Rev 2021; 41(5): 2804-22.
[http://dx.doi.org/10.1002/med.21725] [PMID: 32815157]
[229]
Agrawal I, Lim YS, Ng SY, Ling SC. Deciphering lipid dysregulation in ALS: From mechanisms to translational medicine. Transl Neurodegener 2022; 11(1): 48.
[http://dx.doi.org/10.1186/s40035-022-00322-0] [PMID: 36345044]
[230]
Almer G, Guégan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001; 49(2): 176-85.
[http://dx.doi.org/10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X] [PMID: 11220737]
[231]
Yasojima K, Tourtellotte WW, McGeer EG , McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord. Neurology 2001; 57(6): 952-6.
[http://dx.doi.org/10.1212/WNL.57.6.952] [PMID: 11571316]
[232]
Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2003; 17(6): 725-7.
[http://dx.doi.org/10.1096/fj.02-0876fje] [PMID: 12586733]
[233]
Zou YH, Guan PP, Zhang SQ, Guo YS, Wang P. Rofecoxib attenuates the pathogenesis of amyotrophic lateral sclerosis by alleviating cyclooxygenase-2-mediated mechanisms. Front Neurosci 2020; 14: 817.
[http://dx.doi.org/10.3389/fnins.2020.00817] [PMID: 32903591]
[234]
Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther 2005; 7(Suppl 4): S14-22.
[http://dx.doi.org/10.1186/ar1794] [PMID: 16168077]
[235]
Lucas GNC, Leitão ACC, Alencar RL, Xavier RMF, Daher EDF, Silva Junior GB. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Bras Nefrol 2019; 41(1): 124-30.
[http://dx.doi.org/10.1590/2175-8239-jbn-2018-0107] [PMID: 30281062]
[236]
Petrova TV, Akama KT, Van Eldik LJ. Selective modulation of BV-2 microglial activation by prostaglandin E(2). Differential effects on endotoxin-stimulated cytokine induction. J Biol Chem 1999; 274(40): 28823-7.
[http://dx.doi.org/10.1074/jbc.274.40.28823] [PMID: 10497256]
[237]
Kim EJ, Lee JE, Kwon KJ, Lee SH, Moon CH, Baik EJ. Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E2 production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res 2001; 908(1): 1-9.
[http://dx.doi.org/10.1016/S0006-8993(01)02432-5] [PMID: 11457426]
[238]
Almer G, Teismann P, Stevic Z, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002; 58(8): 1277-9.
[http://dx.doi.org/10.1212/WNL.58.8.1277] [PMID: 11971099]
[239]
Nango H, Tsuruta K, Miyagishi H, Aono Y, Saigusa T, Kosuge Y. Update on the pathological roles of prostaglandin E2 in neurodegeneration in amyotrophic lateral sclerosis. Transl Neurodegener 2023; 12(1): 32.
[http://dx.doi.org/10.1186/s40035-023-00366-w] [PMID: 37337289]
[240]
Iłżecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2003; 108(2): 125-9.
[http://dx.doi.org/10.1034/j.1600-0404.2003.00102.x] [PMID: 12859290]
[241]
Kosuge Y, Miyagishi H, Yoneoka Y, et al. Pathophysiological role of prostaglandin E2-induced up-regulation of the EP2 receptor in motor neuron-like NSC-34 cells and lumbar motor neurons in ALS model mice. Neurochem Int 2018; 119: 132-9.
[http://dx.doi.org/10.1016/j.neuint.2017.06.013] [PMID: 28687401]
[242]
Miyagishi H, Kosuge Y, Yoneoka Y, et al. Prostaglandin E2-induced cell death is mediated by activation of EP2 receptors in motor neuron-like NSC-34 cells. J Pharmacol Sci 2013; 121(4): 347-50.
[http://dx.doi.org/10.1254/jphs.12274SC] [PMID: 23514786]
[243]
Amaradhi R, Mohammed S, Banik A, Franklin R, Dingledine R, Ganesh T. Second-generation prostaglandin receptor EP2 antagonist, TG8-260, with high potency, selectivity, oral bioavailability, and anti-inflammatory properties. ACS Pharmacol Transl Sci 2022; 5(2): 118-33.
[http://dx.doi.org/10.1021/acsptsci.1c00255] [PMID: 35187419]
[244]
Jiang J, Yu Y, Kinjo ER, Du Y, Nguyen HP, Dingledine R. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology 2019; 149: 149-60.
[http://dx.doi.org/10.1016/j.neuropharm.2019.02.011] [PMID: 30763657]
[245]
Minhas PS, Latif-Hernandez A, McReynolds MR, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature 2021; 590(7844): 122-8.
[http://dx.doi.org/10.1038/s41586-020-03160-0] [PMID: 33473210]
[246]
Shinozawa T, Urade Y, Maruyama T, Watabe D. Tetranor PGDM analyses for the amyotrophic lateral sclerosis: Positive and simple diagnosis and evaluation of drug effect. Biochem Biophys Res Commun 2011; 415(4): 539-44.
[http://dx.doi.org/10.1016/j.bbrc.2011.10.045] [PMID: 22027143]
[247]
Kondo M, Shibata T, Kumagai T, et al. 15-Deoxy-Δ 12,14 -prostaglandin J 2 : The endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA 2002; 99(11): 7367-72.
[http://dx.doi.org/10.1073/pnas.112212599] [PMID: 12032289]
[248]
Thonhoff JR, Gao J, Dunn TJ, Ojeda L, Wu P. Mutant SOD1 microglia-generated nitroxidative stress promotes toxicity to human fetal neural stem cell-derived motor neurons through direct damage and noxious interactions with astrocytes. Am J Stem Cells 2011; 1(1): 2-21.
[PMID: 23671793]
[249]
Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008; 3(6): 637-48.
[http://dx.doi.org/10.1016/j.stem.2008.09.017] [PMID: 19041780]
[250]
de Boer A S. Genetic validation of a therapeutic target in a mouse model of ALS. Sci Transl Med 2014; 6(248): 248ra104.
[http://dx.doi.org/10.1126/scitranslmed.3009351]
[251]
Okubo K, Hashiguchi K, Takeda T, et al. A randomized controlled phase II clinical trial comparing ONO -4053, a novel DP 1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis. Allergy 2017; 72(10): 1565-75.
[http://dx.doi.org/10.1111/all.13174] [PMID: 28378369]
[252]
Takahashi G, Asanuma F, Suzuki N, et al. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol 2015; 765: 15-23.
[http://dx.doi.org/10.1016/j.ejphar.2015.08.003] [PMID: 26277322]
[253]
Yarlagadda S, Kulis C, Noakes PG, Smythe ML. Hematopoietic prostaglandin D synthase inhibitor PK007 decreases muscle necrosis in DMD mdx model mice. Life (Basel) 2021; 11(9): 994.
[http://dx.doi.org/10.3390/life11090994] [PMID: 34575143]
[254]
Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol 2016; 26(2): 227-36.
[http://dx.doi.org/10.1111/bpa.12350] [PMID: 26780251]
[255]
Tada S, Okuno T, Shimizu M, et al. Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis. Sci Rep 2019; 9(1): 5252.
[http://dx.doi.org/10.1038/s41598-019-41771-4] [PMID: 30918303]
[256]
Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev 2015; 24(138): 630-41.
[http://dx.doi.org/10.1183/16000617.0067-2015] [PMID: 26621977]
[257]
Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007; 26(1): 1-13.
[http://dx.doi.org/10.1016/j.nbd.2006.12.015] [PMID: 17300945]
[258]
Fisher EMC, Greensmith L, Malaspina A, et al. Opinion: more mouse models and more translation needed for ALS. Mol Neurodegener 2023; 18(1): 30.
[http://dx.doi.org/10.1186/s13024-023-00619-2] [PMID: 37143081]
[259]
Ding Q, Kesavan K, Lee KM, et al. Impaired signaling for neuromuscular synaptic maintenance is a feature of motor neuron disease. Acta Neuropathol Commun 2022; 10(1): 61.
[http://dx.doi.org/10.1186/s40478-022-01360-5] [PMID: 35468848]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 83
Html icon 1
Find your institution